Surgical decisions made by 158 women with hereditary breast cancer aged <50 years

European Journal of Surgical Oncology

Volumn 31, Issue 10, 2005, Pages 1112-1118

  Evans, D Gareth R ^a,b   Lalloo, F ^a   Hopwood, P ^c   Maurice, A ^b   Baildam, A ^b   Brain, A ^c   Barr, L ^b   Howell, A ^b,c  

^a ST MARY S HOSPITAL   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

BRCA1; BRCA2; Contralateral; Risk reducing mastectomy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; HEALTH CARE FACILITY; HEALTH SURVEY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL INFORMATION; PATHOGENESIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK MANAGEMENT; RISK REDUCTION; SURGICAL RISK;

ADULT; AGE FACTORS; BREAST NEOPLASMS; CHOICE BEHAVIOR; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MASS SCREENING; MASTECTOMY; MIDDLE AGED; RISK FACTORS;

EID: 29244460635     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2005.05.007     Document Type: Article

References (31)

1. B. Newman M. Austin M. Lee M.-C. King Inheritance of human breast cancer: Evidence for autosomal dominant transmission in high risk families Proc Natl Acad Sci USA 85 1988 3044-3048
2. E.B. Claus N. Risch W.D. Thompson Autosomal dominant inheritance of early-onset breast cancer; implications for risk prediction Cancer 73 1994 643-651
3. Y. Miki J. Swensen D. Shattuck-Eidens A. Futreal K. Harshman S. Tavtigan et al. A strong candidate for the breast and ovarian cancer susceptibility gene, BRCA1 Science 266 1994 66-71
4. R. Wooster G. Bignell J. Lancaster S. Swift S. Seal J. Mangion et al. Identification of the breast cancer gene BRCA2 Nature 378 1995 789-791
5. A. Antoniou P.D. Pharoah S. Narod H.A. Risch J.E. Eyfjord J.L. Hopper et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies Am J Hum Genet 72 2003 1117-1130
6. L. Tabár G. Faberberg N.E. Day L. Holmberg What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-county breast cancer screening trial Br J Cancer 55 1987 547-551
7. L. Tabár G. Fagerberg H.H. Chen S.W. Duffy C.R. Smart A. Gad et al. Efficacy of breast cancer screening by age Cancer 75 1995 2507-2517
8. Swedish Cancer Society and the Swedish National Board of Health and Welfare Breast-cancer screening with mammography in women aged 40-49 years Int J Cancer 68 1991 693-699
9. D.F. Easton D. Ford D.T. Bishop Breast Cancer Linkage Consortium Breast and ovarian cancer incidence in BRCA1-mutation carriers Am J Hum Genet 56 1995 265-271
10. D. Eccles P. Simmonds J. Goddard M. Coultas S. Hodgson F. Lalloo et al. Familial breast cancer: An investigation into the outcome of treatment for early stage disease Fam Cancer 1 2001 65-72
11. M. Robson T. Svahn B. McCormick P. Borgen C.A.. Hudis L. Norton et al. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: A clinic-based series Cancer 103 1 2005 44-51
12. K. Metcalfe H.T. Lynch P. Ghadirian N. Tung I. Olivotto E. Warner et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers J Clin Oncol 22 2004 2328-2335
13. S.K. McDonnell D.J. Schaid J.L. Myers C.S. Grant J.H. Donohue J.E. Woods et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer J Clin Oncol 19 2001 3938-3943
14. M.D. Schwartz C. Lerman B. Brogan B.N. Peshkin C.H. Halbert T. DeMarco et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients J Clin Oncol 22 2004 1823-1829
15. M. Dorval A.F. Patenaude K.A. Schneider S.A. Kieffer L. DiGianni K.J. Kalkbrenner et al. Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: findings from p53 and BRCA1 testing programs J Clin Oncol 18 2000 2135-2142
16. A. Bish S. Sutton C. Jacobs S. Levene A. Ramirez S. Hodgson Changes in psychological distress after cancer genetic counselling: A comparison of affected and unaffected women Br J Cancer 86 2002 43-50
17. J. Peto T.M. Mack High constant incidence in twins and other relatives of women with breast cancer Nat Genet 26 2000 411-414
18. M. Baum A. Buzdar J. Cuzick J. Forbes J. Houghton A. Howell et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (arimidex, tamoxifen Alone or in combination) trial efficacy and safety update analyses Cancer 98 2003 1802-1810
19. G. Mitchell A. Ardern-Jones M.M. Kissin R. Taylor R.A. Eeles A paradox: urgent BRCA genetic testing Fam Cancer 1 2001 25-29
20. J.N. Weitzel S.M. McCaffrey R. Nedelcu D.J. Macdonald K.R. Blazer C.A. Cullinane Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis Arch Surg 138 2003 1323-1328
21. S.R. Lakhani M.J. van de Vijver J. Jacquemier T.J. Anderson P.P. Osin L. McGuffog et al. The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2 J Clin Oncol 20 2002 2310-2318
22. S.A. Narod J.S. Brunet P. Ghadirian M. Robson K. Heimdal S.L. Neuhausen et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Hereditary Breast Cancer Clinical Study Group Lancet 356 2000 1876-1881
23. L.C. Verhoog C.T. Brekelmans C. Seynaeve E.J. Meijers-Heijboer J.G. Klijn Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer Br J Cancer 83 2000 384-386
24. H. Meijers-Heijboer C.T. Brekelmans M. Menke-Pluymers C. Seynaeve A. Baalbergen C. Burger et al. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation J Clin Oncol 21 2003 1675-1681
25. NICE and National Collaborating Centre for Primary Care Clinical guidelines and evidence review for the classification and care of women at risk of familial breast cancer 2004
26. American Society of Clinical Oncology Statement of the American Society of clinical oncology: Genetic testing for cancer susceptibility J Clin Oncol 14 1996 1730-1736
27. E. Lobb B. Meiser Genetic counselling and prophylactic surgery in women from families with hereditary breast or ovarian cancer Lancet 363 9424 2004 1841-1842
28. P. Moller A. Borg D.G. Evans N. Haites M.M. Reis H. Vasen et al. Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy Int J Cancer 101 6 2002 555-559
29. T.R. Rebbeck H.T. Lynch S.L. Neuhausen S.A. Narod L. Van't Veer J.E. Garber et al. Reduction in cancer risk after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers N Engl J Med 346 2002 1616-1622
30. F. Lalloo A. Baildam A. Brain P. Hopwood D.G. Evans A. Howell A protocol for preventative mastectomy in women with an increased lifetime risk of breast cancer Eur J Surg Oncol 26 7 2000 711-713
31. C.M. Contant M.B. Menke-Pluijmers C. Seynaeve E.J. Meijers-Heijboer J.G. Klijn L.C. Verhoog et al. Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation Eur J Surg Oncol 28 6 2002 627-632